A double-blind crossover study in individuals with type 2 diabetes
Published ahead of print at http://care.diabetesjournals.org on 2 February 2007. DOI: 10.2337/dc06-1328. Clinical trial reg. no. ISRCTN34091554, clinicaltrials.gov, and at clinicalstudyresults.org, no. BIASP-1466.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc06-1328.
P.G.M. has received lectures fees from and been a member of advisory boards for Novo Nordisk. J.D.D. has received honoraria
from and been a member of advisory boards for Novo Nordisk. A.D.M. has received renumeration to participate on the speakers
bureau of Novo Nordisk and was a clinical trial investigator for the REACH study. P.D.W. receives payment for providing statistical
consultancy services to Novo Nordisk. S.R.H. has received fees for giving lectures at symposia sponsored by Novo Nordisk and
for participating in research activities sponsored by Novo Nordisk and has served on national and international advisory boards
sponsored by Novo Nordisk. Novo Nordisk manufactures and markets the insulin products used in the REACH trial.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.